ANTI-SEZ6 ANTIBODY DRUG CONJUGATES AND METHODS OF USE

(19)

(11)

EP 3 710 485 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	23.06.2021 Bulletin 2021/25

(45)	Mention of the grant of the patent:
	31.03.2021 Bulletin 2021/13

(21)	Application number: 19732174.8

(22)	Date of filing: 30.05.2019

(51)

International Patent Classification (IPC):

C07K 16/28^(2006.01)

A61K 47/68^(2017.01)

(86)	International application number:
	PCT/US2019/034701

(87)	International publication number:
	WO 2019/232241 (05.12.2019 Gazette 2019/49)

(54)	ANTI-SEZ6 ANTIBODY DRUG CONJUGATES AND METHODS OF USE ANTI-SEZ6-ANTIKÖRPER-ARZNEIMITTELKONJUGATE UND DEREN VERWENDUNGSMETHODEN CONJUGUES DES ANTICORPS ANTI-SEZ6 ET LEURS PROCEDES D'UTILISATION

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	KH MA MD TN

(30)

Priority:

30.05.2018 US 201862678061 P

(43)	Date of publication of application:
	23.09.2020 Bulletin 2020/39

(60)	Divisional application:
	21157876.0

(73)	Proprietor: AbbVie Stemcentrx LLC
	North Chicago, IL 60064-6400 (US)

(72)	Inventors:
	LIU, David Pacifica, California 94044 (US) GAVRILYUK, Julia San Diego,CA 92130 (US) SCHAMMEL, Alexander San Francisco, California 94114 (US)

(74)	Representative: J A Kemp LLP
	14 South Square Gray's Inn London WC1R 5JJ London WC1R 5JJ (GB)

(56)

References cited: :

WO-A1-2013/126810
WO-A1-2016/141285
WO-A1-2017/112803
WO-A2-2005/089808

WO-A1-2015/031698
WO-A1-2016/172273
WO-A2-03/092623

JAIN NARESHKUMAR ET AL: "Current ADC Linker Chemistry", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 32, no. 11, 11 March 2015 (2015-03-11), pages 3526-3540, XP035553874, ISSN: 0724-8741, DOI: 10.1007/S11095-015-1657-7 [retrieved on 2015-03-11]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).